The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in Germany

Krahn, 1995, The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the manitoba follow-up study, Am J Med, 95, 476, 10.1016/S0002-9343(99)80348-9 Wolf, 1991, Atrial fibrillation as an independent risk factor for stroke: the framingham study, Stroke, 22, 983, 10.1161/01.STR.22.8.983 Hart, 1999, Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis, Ann Intern Med, 131, 492, 10.7326/0003-4819-131-7-199910050-00003 Thrall, 2006, Quality of life in patients with atrial fibrillation: a systematic review, Am J Med, 119, 448, 10.1016/j.amjmed.2005.10.057 Go, 2001, Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study, JAMA, 285, 2370, 10.1001/jama.285.18.2370 Stewart, 2001, Population prevalence, incidence, and predictors of atrial fibrillation in the renfrew/paisley study, Heart, 86, 516, 10.1136/heart.86.5.516 Heeringa, 2006, Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, Eur Heart J, 27, 949, 10.1093/eurheartj/ehi825 Benjamin, 1994, Independent risk factors for atrial fibrillation in a population-based cohort. The framingham heart study, J Am Med Assoc, 271, 840, 10.1001/jama.1994.03510350050036 Chan, 2006, Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation, J Am Coll Cardiol, 47, 2513, 10.1016/j.jacc.2006.01.070 Coleman, 2004, Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation, Pharmacoeconomics, 22, 877, 10.2165/00019053-200422130-00005 de-Paola, 2003, Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation, Int J Cardiol, 88, 157, 10.1016/S0167-5273(02)00380-7 Zarkin, 1997, The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm, Am J Manag Care, 3, 1387 Lightowlers, 1998, Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke, Stroke, 29, 1827, 10.1161/01.STR.29.9.1827 Le-Heuzey, 2004, Cost of care distribution in atrial fibrillation patients: the COCAF study, Am Heart J, 147, 121, 10.1016/S0002-8703(03)00524-6 Stewart, 2004, Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK, Heart, 90, 286, 10.1136/hrt.2002.008748 Coyne, 2006, Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States, Value Health, 9, 348, 10.1111/j.1524-4733.2006.00124.x Fuster, 2001, Eur Heart J, 22, 1852, 10.1053/euhj.2001.2983 Schuchert, 2003, Kommentar zu den ACC/AHA/ESC-leitlinien 2001 zur prävention arterieller thromboembolien bei Patienten mit Vorhofflimmern, Z Kardiol, 92, 694, 10.1007/s00392-003-0992-6 Fuster, 2001, Circulation, 104, 2118, 10.1161/circ.104.17.2118 Nieuwlaat, 2005, Atrial fibrillation management: a prospective survey in ESC member countries: the Euro heart survey on Atrial Fibrillation, Eur Heart J, 26, 2422, 10.1093/eurheartj/ehi505 Marshall, 2004, Cost-effectiveness of rhythm versus rate control in atrial fibrillation, Ann Intern Med, 141, 653, 10.7326/0003-4819-141-9-200411020-00005 Hagens, 2004, Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation—results from the Rate Control versus Electrical cardioversion (RACE) study, Eur Heart J, 25, 1542, 10.1016/j.ehj.2004.06.020 Kassenärztliche Bundesvereinigung (KBV) Verband der Angestellten-Krankenkassen GmbH German Deutscher Taylor, 2007, Acute coronary syndromes in Europe: 1-year costs and outcomes, Current Med Res Opin, 23, 495, 10.1185/030079906X167462 Benjamin, 1994, Independent risk factors for atrial fibrillation in a population-based cohort. The framingham heart study, JAMA, 271, 840, 10.1001/jama.1994.03510350050036 Wolf, 1991, Atrial fibrillation as an independent risk factor for stroke the framingham study, Stroke, 22, 983, 10.1161/01.STR.22.8.983 Hart, 2003, Lessons from the stroke prevention in Atrial Fibrillation trials, Ann Intern Med, 138, 831, 10.7326/0003-4819-138-10-200305200-00011 Heeringa, 2006, Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, Eur Heart J, 27, 949, 10.1093/eurheartj/ehi825 Bruggenjurgen, 2007, The impact of Atrial Fibrillation on the cost of stroke: the Berlin acute stroke study, Value Health, 10, 137, 10.1111/j.1524-4733.2006.00160.x Choi, 2002, A method for comparing and combining cost-of-illness studies: an example from cardiovascular disease, Chronic Dis Can, 23, 47 Weintraub, 2004, Cost of heart failure in patients receiving beta-blockers and angiotensin-converting enzyme inhibitors, Clin Drug Investig, 24, 255, 10.2165/00044011-200424050-00002 Deplanque, 2004, Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study, Br J Clin Pharmacol, 57, 798, 10.1111/j.1365-2125.2004.02086.x Deplanque, 1999, Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I study investigators, Heart, 82, 563, 10.1136/hrt.82.5.563 Laguna, 2004, P. Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study, Ann Emerg Med, 44, 3, 10.1016/j.annemergmed.2004.01.010 Stöllberger, 1999, Antithrombotische therapie bei vorhofflimmern und zusätzlichen schlaganfall-/embolie-risikofaktoren. CORSurvey-erhebung. Antithrombotic therapy in atrial fibrillation and additional stroke/embolism risk factors. CORSurvey study, Z Kardiol, 88, 442 Samsa, 2000, Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities, Arch Intern Med, 160, 967, 10.1001/archinte.160.7.967 McCormick, 2001, Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting, Arch Intern Med, 161, 2458, 10.1001/archinte.161.20.2458 Nair, 2005, Antithrombotic therapy in atrial fibrillation: an assessment of compliance with guidelines, N Z Med J, 118, 1258 Lim, 2005, Differences in quality of care among patients hospitalized with atrial fibrillation as primary or secondary cause for admission, Int J Qual Health Care, 17, 255, 10.1093/intqhc/mzi026 Murdoch, 2005, Are atrial fibrillation guidelines altering management? A community based study, Scot Med J, 50, 166, 10.1177/003693300505000409 Bungard, 2000, Why do patients with atrial fibrillation not receive warfarin?, Arch Intern Med, 160, 41, 10.1001/archinte.160.1.41 Ezekowitz, 2003, Anticoagulation in management of atrial fibrillation, Curr Opin Cardiol, 18, 26, 10.1097/00001573-200301000-00004 Jenkins, 2005, Quality of life in atrial fibrillation: the atrial fibrillation follow-up investigation of rhythm management affirm. study, Am Heart J, 149, 112, 10.1016/j.ahj.2004.03.065 Hagens, 2004, Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation—esults from the Rate Control versus Electrical cardioversion (RACE)study, Eur Heart J, 25, 1542, 10.1016/j.ehj.2004.06.020 Hohnloser, 2000, Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial, Lancet, 356, 1789, 10.1016/S0140-6736(00)03230-X Jo, 2003, Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study, J Am Coll Cardiol, 41, 1690, 10.1016/S0735-1097(03)00332-2